What is Orgenesis?
Orgenesis operates through its innovative POCare Platform, designed to streamline the processing and production of CGTs. The platform integrates a pipeline of licensed therapeutics with automated production systems and a collaborative network of healthcare stakeholders. By identifying promising new therapies and leveraging its platform, Orgenesis aims to create a rapid, globally standardized pathway for these treatments to reach a broad patient population. The company's strategy emphasizes lowered costs through efficient, scalable, and decentralized production, facilitated by its POCare Network, which unites patients, physicians, research institutions, and industry partners for harmonized clinical development and regulated manufacturing.
How much funding has Orgenesis raised?
Orgenesis has raised a total of $55M across 2 funding rounds:
Unspecified
$50M
Private Equity
$5M
Unspecified (2022): $50M with participation from Metalmark Capital
Private Equity (2023): $5M led by Metalmark Capital Partners
Key Investors in Orgenesis
Metalmark Capital
Metalmark Capital is a growth equity investment firm that focuses on founder-owned businesses in the middle market, aiming to build long-term value through active and collaborative partnerships.
Metalmark Capital Partners
Metalmark Capital Partners is an investment entity likely focused on providing capital for growth-stage companies, aligning with Orgenesis's strategic objectives.
What's next for Orgenesis?
The recent major strategic investment signals a pivotal growth phase for Orgenesis, likely enabling the company to accelerate the expansion of its POCare Platform and Network. This capital infusion is expected to bolster its efforts in bringing novel cell and gene therapies to market more efficiently and affordably. Strategic partnerships and further network development will be crucial as Orgenesis continues its mission to decentralize the production of advanced medical treatments, positioning itself as a key player in the evolving landscape of accessible healthcare solutions.
See full Orgenesis company page
